Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTDT of Anastrozole in Early Stage Breast Cancer
NCT04294225Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in breast cancer, sponsored by Mayo Clinic. Primary endpoint: Percentage of Participants With Adequate Estrogen Suppression After 8 Weeks of Adjuvant Anastrozole 10 mg Daily. Started Apr 2020; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04294225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294225.